Akèy › Kansè lestomak › Tennessee
Etid klinik pou Kansè lestomak nan Tennessee
30 etid pou Kansè lestomak ap chèche patisipan nan sit nan Tennessee.
Vil nan Tennessee
Tèks ofisyèl etid la (Anglè)
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07283939A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06760819A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
Ap rekriteFaz 1
Laj 19 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06586957A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06172478A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07221149Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- Sarah Cannon Research Institute (SCRI) - Oncology Partners, Nashville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07700979IKS014 in Advanced Solid Tumors That Express HER2
- Tennessee Oncology, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05872295Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Vanderbilt University Medical Center, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- Vanderbilt Ingram Cancer Center, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT05523947Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Nashville
Ap rekriteFaz 2
Laj 18 a 130 · Tout sèks · Mizajou Sep 23, 2026 · NCT05489211Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Sarah Cannon Research Institue, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05267626Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898A Phase 1/1b Study of IAM1363 in HER2 Cancers
- SCRI Oncology Partners, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06253871Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Nashville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07431281A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 13, 2026 · NCT07066657A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- The University Of Tennessee Health Science Center, Memphis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT03526835A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT06131840A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 15, 2026 · NCT06657144A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT06695845A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- US Oncology Research LLC, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT04389632Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
- Vanderbilt University Medical Center, Nashville
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou May 8, 2026 · NCT06828588Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT06239194Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
- Veterans Affairs Medical Center - Nashville, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 5, 2026 · NCT00899626A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Vanderbilt University Medical Center, Nashville
- HCA Midwest Health, Nashville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Feb 27, 2026 · NCT06532006A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1/2
Laj 18 a 85 · Tout sèks · Mizajou Jan 29, 2026 · NCT06055439cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist (BHMCC), Memphis
- Vanderbilt-Ingram Cancer Center, Nashville
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05366881SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Tennessee Oncology, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2025 · NCT05941507Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.